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ABSTRACT
The potent aggrecanase ADAMTS-5 is constitutively secreted by chondrocytes, but it is rapidly
endocytosed in normal cartilage via the cell surface endocytic receptor LRP1. Therefore it is difficult to
detect the total ADAMTS-5 activity produced. In this study, we isolated a monoclonal anti-ADAMTS-5
antibody 1B7 that blocks LRP1-mediated internalization without affecting the aggrecanolytic activity.
Addition of 1B7 to cultured human chondrocytes revealed the full aggrecanolytic activity of ADAMTS-5
generated by the cells. 1B7 is a useful tool to estimate the ADAMTS-5 activity and to identify its potential
roles in the tissues.
Abbreviations: ADAMTS, adamalysin-like metalloproteinases with thrombospondin motifs; AP, alkaline phospha-
tase; Cat, catalytic domain; CysR, Cys-rich domain; Dis, disintegrin domain; ECM, extracellular matrix; LRP1, low-den-
sity lipoprotein receptor-related protein 1; OA, osteoarthritis; RAP, receptor-associated protein; scFv, single chain
variable fragment; Sp, spacer; TIMP-3, tissue inhibitor of metalloproteinase-3; TS, thrombospondin-like
KEYWORDS
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Introduction
ADAMTS-5 (a disintegrin and metalloproteinase with
thrombospondin motifs 5) is a potent aggrecanase in carti-
lage and participates in the progression of osteoarthritis
(OA).1-5 It is also expressed in many other tissues6 and
cleaves extracellular matrix (ECM) proteoglycans such as
versican, brevican, decorin, biglycan and fibromodulin.7,8 Its
ability to cleave versican is considered to be important in
cardiac valve development,9 limb morphogenesis,10,11 wound
healing12 and lymphocyte trafficking following influenza
virus infection.13
The expression of ADAMTS-5 has been reported to be regu-
lated at the transcriptional and post-transcriptional levels,14,15
but we have recently found that ADAMTS-5 is constitutively
produced in normal cartilage. However, it is rapidly cleared by
the chondrocytes via the endocytic receptor, low-density lipo-
protein receptor-related protein 1 (LRP1), and degraded subse-
quently.16,17 Because of its clearance, it is difficult to detect
ADAMTS-5 in normal steady-state of the tissue, but it probably
functions for a short, finite period of time to maintain normal
turnover of cartilage matrix components.
LRP1 is a type 1 transmembrane protein consisting of a 515-
kDa a-chain containing extracellular ligand-binding domains
and an 85-kDa b-chain containing a transmembrane domain
and a cytoplasmic domain. Both chains are derived from the
same precursor and non-covalently attached on the cell surface.
More than 50 ligands for LRP1 have been reported, including
lipoproteins, ECM proteins, growth factors, cell surface receptors,
proteinases, proteinase inhibitors and secreted intracellular pro-
teins.18 Because LRP1 is widely expressed in different tissues and
cell types, it may play an important role in regulating
ADAMTS-5 activity not only in cartilage but also in other tissues
such as blood vessels, lung, adipose tissue and brain.6,18,19 How-
ever, it is difficult to investigate the biologic significance of
ADAMTS-5 endocytosis because there are no tools available to
specifically block the endocytosis of the enzyme.
ADAMTS-5 is a multidomain metalloproteinase consisting
of a catalytic (Cat), a disintegrin (Dis), a first thrombospondin-
like (TS) domain, a spacer (SP) and a second C-terminal TS
domain. We previously reported that the first TS and Sp
domains are responsible for ADAMTS-5 binding to LRP1.20
The aims of this study were to isolate a monoclonal anti-
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ADAMTS-5 antibody that selectively blocks the interaction
with LRP1 and to detect the aggrecanolytic activity of
ADAMTS-5 that is masked by the endocytic clearance. We
screened the battery of monoclonal antibodies for ADAMTS-5
that were isolated from a phage-displayed single-chain anti-
body library17 and obtained one that blocks ADAMTS-5 endo-
cytosis without affecting the enzyme’s aggrecanolytic activity.
Results
We first selected anti-ADAMTS-5 scFv-Fc antibodies (i.e. sin-
gle-chain variable fragments fused with the crystallizable frag-
ment of immunoglobulin) that have no major inhibitory effect
on the aggrecanolytic activity of ADAMTS-5 from the pool of
monoclonal antibodies that were previously isolated from the
phage-displayed single chain antibody library.17 As shown in
Fig. 1A, 11 anti-ADAMTS-5 antibodies did not show a major
effect on the aggrecanolytic activity. We then examined them
for their ability to block the binding of ADAMTS-5 to
immobilized LRP1. Among them, one antibody, designated
1B7, effectively inhibited the binding of ADAMTS-5 to LRP1
and »50% inhibition was detected at the concentration of
100 nM (Fig. 1B). In this assay, the LRP ligand-binding antago-
nist, receptor-associated protein (RAP) exhibited »75% inhibi-
tion at 100 nM (Fig. 1B). The dose-dependent binding of
ADAMTS-5 to LRP1 was markedly reduced in the presence of
100 nM 1B7, whereas the binding of ADAMTS-4 and of tissue
inhibitor of metalloproteinases 3 (TIMP-3) to LRP1 was not
blocked (Fig. 1C). As expected, RAP (100 nM) blocked the
binding of all 3 ligands.
Tomap the 1B7 binding site in ADAMTS-5, we tested a series
of domain deletion mutants of ADAMTS-5 (Fig. 2A) for their
ability to bind to 1B7 by using Western blotting. As shown in
Fig. 2B, all forms of ADAMTS-5 reacted with 1B7, suggesting
that the antibody reacts with the Cat/Dis domains. The antibody
reacted with all these forms only when the enzyme proteins
were non-reduced (data not shown). Biolayer interferometry
analysis showed that ADAMTS-5–2 that lacks the
Figure 1. Screening of an anti-ADAMTS-5 antibody that blocks the interaction with LRP1. (A) Effect of anti-ADAMTS-5 antibodies on purified aggrecan degradation by
ADAMTS-5. Purified bovine aggrecan (50 mg) was incubated with FLAG-tagged ADAMTS-5–2 (2 pM) in the absence (none) or presence of antibodies (each 500 nM) or N-
TIMP-3 (10 nM) at 37C for 2 h. The reactions were terminated with 50 mM EDTA and the reaction products were deglycosylated and subjected to Western blot analysis
using anti-AGEG aggrecan neoepitope antibody. Densitometric analysis of immunoreactive bands of aggrecan fragments detected was then performed and the mean for
the fragments generated in the absence of the antibodies was taken as 100%. Each point represents an individual experiment. (B) Effect of anti-ADAMTS-5 antibodies on
ADAMTS-5 binding to LRP1. Full-length LRP1 was coated onto microtiter plates, and the binding of biotinylated ADAMTS-5–2 (6 nM) in the absence or presence of anti-
ADAMTS-5 antibodies (each 100 nM) or RAP (100 nM) was measured using AP-conjugated streptavidin described in Section 2.4. The amount of ADAMTS-5 bound to LRP1
was expressed as % of the amount of ADAMTS-5 bound to LRP1 in the absence of antibodies or RAP. Bars represent the mean § SD (n D 3) (C) Full-length LRP1 was
coated onto microtiter plates and binding of ADAMTS-5–2 (left panel), ADAMTS-4 lacking C-terminus spacer domain (middle panel), or TIMP-3 (right panel) in the absence
or presence of 1B7 or RAP (each 100 nM) was measured using anti-FLAG M2 antibody and a horseradish peroxidase-conjugate secondary antibody.
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C-terminal TS domain bound to 1B7 with a KD value of 70
§ 10 nM [kon: (8.4 § 2.1) £ 103 M¡1sec¡1; koff: (5.9 § 0.8) £
10¡4sec¡1] and that ADAMTS-5–5 consisting of only Cat and
Dis domains (ADAMTS-5–5) bound with a KD value of
150 § 24 nM [kon: (11 § 2) x 103 M¡1sec¡1; koff: (18 § 0.7) £
10¡4 sec¡1] (Fig. 2C and D).
To investigate whether 1B7 inhibits ADAMTS-5 endocyto-
sis, purified ADAMTS-5 was added to the cultured human
chondrocytes and the amounts of ADAMTS-5 that remained
in the medium were monitored by Western blotting as
described previously.16 As a control we used the antibody 2A3,
which neither blocks the binding of ADAMTS-5 to LRP1 nor
inhibits the enzyme activity (Fig. 1A and B). ADAMTS-5 endo-
cytosis was markedly inhibited by 100 nM 1B7 and 500 nM
RAP, but not by 100 nM 2A3 (Fig. 3A). A dose-dependent inhi-
bition study showed a partial inhibition with 20 nM 1B7 and a
similarly strong inhibition with 100 nM and 250 nM 1B7, indi-
cating that 100 nM 1B7 is sufficient to block ADAMTS-5 endo-
cytosis almost completely (Fig. 3B).
We then investigated whether 1B7 increases the aggrecano-
lytic activity of the endogenously produced ADAMTS-5 by
blocking its endocytosis. In these experiments, native bovine
aggrecan was added to the medium of cultured human chondro-
cytes as substrate to detect aggrecanolytic activity, and the aggre-
canase-specific cleavage of aggrecan core protein was measured
by Western blotting using the anti-AGEG neoepitope antibody.
Cultured chondrocytes treated with human IgG and those
treated with non-inhibitory antibody 2A3 exhibited a similar
time-dependent cleavage of aggrecan, which was inhibited by
the N-terminal domain of tissue inhibitor of metalloproteinase-
3 (N-TIMP-3) and 2D3 (Fig. 4A), an inhibitory antibody previ-
ously shown to potently inhibit aggrecanase activity.17 Since
ADAMTS-5 is inhibited almost completely by 2D3 at the con-
centration of 100 nM,17 the residual activity detected in the pres-
ence of 2D3 was due to ADAMTSs other than ADAMTS-5. In
the presence of 1B7, the aggrecan degradation was increased by
about 2.4-fold after 72 h incubation compared with that with
2A3 (Fig. 4A). Quantitative mRNA analysis showed similar lev-
els of LRP1 mRNA in the absence or presence of 1B7 (data not
shown). The 1B7-increased aggrecan degradation was inhibited
by 2D3 to the similar level of control chondrocytes treated with
2D3 (Fig. 4B). Subtraction of the aggrecanolytic activity of non-
Figure 2. Mapping of 1B7 binding sites in the catalytic/disintegrin domains of ADAMTS-5. (A) Schematic representation of FLAG-tagged domain deletion mutants of
ADAMTS-5. (B) ADAMTS-5 deletion forms (100 ng) were run on a 10% polyacrylamide gel under non-reducing conditions. 1B7 (1 mM) was used as a primary antibody
and anti-human immunoglobulin AP-conjugated as a secondary antibody. For comparison, a polyclonal anti-ADAMTS-5 Cat domain antibody8 was used. IB: immunoblot.
(C) Biolayer interferometry analysis showing the interaction of 1B7 with ADAMTS-5–2 (left panel) and ADAMTS-5–5 (right panel). Biotinylated 1B7 (1 mM) was immobilized
on the surface of a streptavidin-coated biosensor and incubated with different concentrations of FLAG-tagged ADAMTS-5–2 (0–400 nM) or ADAMTS-5–5 (50–1600 nM)
and the binding was analyzed in singlicate by biolayer interferometry as reported in the Method section. Fitting curves are overlaid with raw data. (D) The kinetic rate con-
stants and KD values for binding of ADAMTS-5–2 and ADAMTS-5–5 to 1B7.
MABS 597
D
ow
nl
oa
de
d 
by
 [R
oy
al 
Ve
ter
ina
ry
 C
oll
eg
e] 
at 
03
:07
 09
 A
ug
us
t 2
01
7 
ADAMTS-5 aggrecanases from the total activity revealed that
the increase in ADAMTS-5-mediated aggrecan degradation was
much more pronounced in the presence of 1B7 compared with
that in the presence of the non-inhibitory antibody 2A3
(Fig. 4C). These results indicate the extracellular level of
ADAMTS-5 is constant (in a steady-state) in control chondro-
cytes, but the specific blocking of ADAMTS-5 endocytosis accu-
mulates the enzyme extracellularly.
To estimate how much the ADAMTS-5 activity is regulated by
endocytosis, the aggrecanolytic activity observed after 72 h incuba-
tion in the presence of 1B7 was compared with that of purified
ADAMTS-5. The amount of aggrecanolytic activity accumulated
in the 200-ml culture medium during 72 h from 5£ 104 chondro-
cytes in the presence of 1B7 was similar to that detected by a 2-h
incubation of 2 pM recombinant ADAMTS-5–2 (Fig. 4D).
Discussion
Since numerous molecules are endocytosed by LRP1, an agent that
selectively blocks endocytosis of a specific LRP1 ligand is consid-
ered to be a useful tool to investigate the pathophysiological roles
of the molecule. In this study, we characterized a monoclonal
antibody against one of the LRP1 ligands, ADAMTS-5, from a
phage-displayed single-chain antibody library. The antibody 1B7
selectively blocks the interaction of the enzyme with LRP1 without
affecting its aggrecanolytic activity. To date, several examples of
molecules that can interfere with the binding of LRP1 ligand to the
receptor have been reported. For example, Lenting et al.21 identi-
fied a monoclonal antibody that blocks the binding of coagulation
factor VIII to LRP1. RNA-aptamers for pro-urokinase plasmino-
gen activator (pro-uPA)22 and for tissue plasminogen activator
(tPA)23 that inhibit their binding to LRP1 were also reported.
However, the antibody inhibits the proteolytic activity of factor
VIII,21 the former aptamers block the binding of pro-uPA to the
uPA receptor and interfere with pro-uPA activation by plasmin,22
and the latter aptamers inhibit tPA-mediated plasminogen activa-
tion in the presence of a stimulating soluble fibrin fragment.23
Another set of examples is provided by segments of ligand binding
domains of LRP1. The ectodomain of LRP1 harbors 4 clusters
(clusters I-IV) of ligand binding sites, each composed of between 2
and 11 cysteine-rich complement-type repeats that are basic ele-
ment for ligand binding. Chen et al.24 have determined that the N-
terminal half of cluster II without the EGF-like domain (midkine-
trap) has the highest affinity to cell growth factor midkine. This
midkine-trap blocked the internalization of the growth factor and
its translocation to nucleus and prevented tumor cells growth.24
More recently, Scilabra et al.25 reported that the same fragment
also bound to TIMP-3 and prevented the LRP1-mediated internal-
ization of TIMP-3, but not that of ADAMTS-5, ADAMTS-4 or
MMP-13. At the moment, designing molecules that can selectively
block ADAMTS-5 endocytosis by mimicking LRP1 binding
elements remains a challenging task, since many LRP1 ligands,
including ADAMTS-4 and ADAMTS-5, bind to clusters II and IV
and compete with each other for the binding sites.20 This problem
was circumvented by developing the antibody 1B7, and the
treatment of human chondrocytes with 1B7 allowed us to detect
full aggrecanolytic activity of ADAMTS-5 in the medium.
We originally postulated that antibodies that block the
endocytosis of ADAMTS-5 would react with the first TS and
Sp domains of ADAMTS-5, as these domains are responsible
for LRP1 binding.20 However, our study using domain deletion
mutants of ADAMTS-5 revealed that the 1B7 antibody binds
Figure 3. Inhibition of ADAMTS-5 endocytosis by 1B7. (A) Human chondrocytes (n D 3) were cultured with DMEM containing 10 nM of FLAG-tagged ADAMTS-5–2 in the
presence or absence of 1B7 or 2A3 (each 100 nM), or RAP (500 nM) for 0–4 h. ADAMTS-5–2 in the medium was detected by Western blotting using anti-FLAG M2 anti-
body. Upper panel, representative Western blot analysis. Lower panel, quantified data, where the amount of ADAMTS-5 was expressed as % of the amount of the enzyme
at 0 h. Points represent the mean§ SD. Arrows in the blot indicate exogenously added ADAMTS-5–2. (B) Human chondrocytes (nD 3) were cultured with DMEM contain-
ing 10 nM FLAG-tagged ADAMTS-5–2 in the presence of 1B7 (0–250 nM) for 0–4 h, and ADAMTS-5–2 in the media was detected as in (A).
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to the Cat/Dis domains. Since it does not recognize ADAMTS-
5 under reducing conditions, it is likely that it binds to a non-
linear epitope. We speculate 3 possibilities to explain how 1B7
may block the interaction of ADAMTS-5 to LRP1. One possi-
bility is that 1B7 recognizes the Cat/Dis domains of ADAMTS-
5 primary, but it also interacts with the first TS, CysR and Sp
domains, because the affinity of ADAMTS-5–2 is 2.1-fold
higher than ADAMTS-5–5. The second possibility is that anti-
body 1B7 interferes with the interaction between the first TS or
Sp domain and LRP1 by steric hindrance. The third possibility
is that 1B7 allosterically blocks the flexibility between different
ancillary domains, in a binding mode similar to that of a
recently reported anti-ADAMTS-5 antibody.5 Future structural
studies are necessary to understand these possibilities.
Selective inhibition of endocytosis and proteolytic activity of
ADAMTS-5 by the combination of antibodies 1B7 and 2D3
revealed a dynamic cellular regulation of ADAMTS-5 activity,
i.e., constitutive production and a rapid endocytosis. Since
aggrecanolytic activity of ADAMTS-5 in the cultured human
chondrocytes was exponentially increased when endocytosis
was blocked, 1B7 could be useful to identify new substrates in
this system and in other tissues. We propose that dysregulation
of the LRP1-mediated endocytic pathway is likely to disrupt
normal turnover of extracellular molecules. Indeed, we previ-
ously found that LRP1-mediated endocytosis was impaired in
OA cartilage, which resulted in increased extracellular activity
of ADAMTS-5 and degradation of cartilage matrix.16 However,
the exact role of ADAMTS-5 in the development of OA is not
clearly understood because the uptake of most LRP1 ligands,
including ADAMTS-4, MMP-2, MMP-9, MMP-13, TIMP-3,
and connective tissue growth factor (CCN-2),15,20,26-28 is pre-
vented. Thus, 1B7 should be a useful tool to elucidate the path-
ological impact of ADAMTS-5 by selectively blocking its
endocytic pathway. In contrast to OA, the overexpression of
LRP1 in atherosclerotic lesions has been reported in humans
and in several animal models,29 and the elevated ADAMTS-5
activity is considered to play an important role in turnover of
vascular proteoglycans and keep the lipoprotein level low in
aorta.30 These studies suggest a pathological role of depletion of
ADAMTS-5 activity due to its excess removal from the tissue.
We are currently testing whether 1B7 can penetrate the tissues
because it may be beneficial in these pathological conditions,
rescuing the enzyme from its endocytic clearance.
Materials and methods
Preparation of recombinant proteins and antibodies
Various forms of domain deleted human ADAMTS-5,8 human
ADAMTS-4 lacking C-terminus Sp domain,31 TIMP-332 were
prepared as recombinant proteins with a FLAG-tag at C-termi-
nus as described previously. Human N-terminal domain of
Figure 4. Detection of the total aggrecanolytic activity of ADAMTS-5 produced by
human chondrocytes. (A) Human chondrocytes (n D 3) were cultured with DMEM
containing purified bovine aggrecan (100 mg/ml) in the presence of human IgG,
1B7, 2A3, 2D3 or N-TIMP-3 (each 100 nM) for 0–72 h. The conditioned media were
deglycosylated and subjected to Western blot analysis using anti-AGEG aggrecan
neoepitope antibody. Upper panel, representative Western blot analysis. Lower
panel, quantification of aggrecan fragments, where the mean value for the frag-
ments generated after 48 h incubation with human IgG was taken as 1. (B) Human
chondrocytes (n D 3) were cultured with DMEM containing purified bovine aggre-
can (100 mg/ml) and 2A3 or 1B7 (each 100 nM) in the presence of human IgG
(-2D3) or 2D3 (each 100 nM) for 0–60 h. The aggrecanolytic activity in the culture
was detected as in A. Upper panel, representative Western blot analysis. Lower
panel, quantification of aggrecan fragments, where the mean value for the frag-
ments generated after 40 h incubation with 2A3 in the absence of 2D3 was taken
as 1. (C) Relative amount of ADAMTS-5-mediated aggrecan degradation was esti-
mated by subtracting the amount of aggrecan degradation in the presence of 2D3
from that in the absence of 2D3 detected in B. (D) Purified bovine aggrecan
(100 mg/ml) was incubated with purified ADAMTS-5–2 (0–2 pM) for 2 h and the
amount of aggecan fragments was compared with that in the medium of human
chondrocytes after 72 h incubation with 1B7. The mean value for the amount of
the fragments after 2 h incubation with 1 pM ADAMTS-5–2 was taken as 1. Bars
represent the mean § SD , p < 0.05; unpaired t test.
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TIMP-3 was prepared as reported.32 The concentrations of
active enzymes were determined by titration against known
concentrations of N-TIMP-3 using quenched-fluorescent pep-
tides. Rabbit anti-AGEG antibodies that recognize the
N-terminal AGEG generated by aggrecanase cleavage of bovine
aggrecan at Glu1771-Ala1772,33 and RAP16 were prepared as
reported. Bovine nasal cartilage aggrecan was prepared accord-
ing to Hascall and Sajdera.34 The polyclonal rabbit anti-
ADAMTS-5 Cat domain recognizing the peptide sequence
CEETFGSTEDKRL (amino acids 410– 422) has been described
previously.8 The anti-ADAMTS-5 antibodies were expressed in
HEK293-F cells (Invitrogen) as single-chain variable fragments
fused with the crystallizable fragment of immunoglobulin
(scFv-Fc) and purified.35 Western Blue stabilized substrate (5-
bromo-4-chloro-3-indolyl-1-phosphate and nitroblue tetrazo-
lium) for alkaline phosphatase (AP), anti-mouse AP-linked
antibody (S3721), anti-human immunoglobulin AP-linked
(S3821) and anti-rabbit AP-linked (S3731) antibodies were
from Promega and solubilized and purified full-length human
LRP1 from was from BioMac (#04–03). Unless stated other-
wise, all chemicals were purchased from Sigma-Aldrich.
Aggrecan digestion assay
Aggrecan digestion assay was performed as previously
reported.17 Briefly, 50 mg of native aggrecan (final concentra-
tion 670 nM) were incubated with ADAMTS-5–2 (0–2 pM) in
TNC buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM
CaCl2 and 0.02% NaN3) containing 0.05% (v/v) Brij-35 at 37C
for 2 h. Aggrecan was deglycosylated in sodium acetate buffer
with chondroitinase ABC and endo-b-galactosidase (each 0.01
unit/100 mg of aggrecan) for 24 h at 37C. Aggrecan was then
precipitated using ice-cold acetone and analyzed by Western
blotting using the rabbit polyclonal anti-AGEG antibody.
Immune signals for the aggrecan fragments were acquired
using ImageScannerIII (GE Healthcare) and quantified with
ImageJ quantification software.
Phage display selections
Phage display selections using human recombinant ADAMTS-
5 as an antigen were previously reported.17 Biotinylated
ADAMTS-5–2 was used to screen a naive human scFv phage-
display library.36 The library was previously deselected against
flag peptide (5 mM) to remove phages recognizing the flag tag
on the recombinant antigen. Following 2 rounds of solution-
phase selection, the eluted polyclonal scFv population was
cloned into pBIOCAM5 expression vector for mammalian
expression of scFv–Fc fusions and transformed into DH5a
Escherichia coli.35 Individual clones isolated were transfected
into HEK293-F cells (Invitrogen). Conditioned medium was
then screened against biotinylated recombinant ADAMTS-5–2
(50 nM). Bound antibodies were detected by time-resolved
fluorescence using europium-labeled anti-human antibody
(1244–330, PerkinElmer) and dissociation-enhanced lantha-
nide fluorescence immunoassay enhancement solution (Perki-
nElmer) followed by europium signal acquisition (330 nm
excitation, 620 nm emission) on a plate reader. Following initial
screening, selected anti-ADAMTS-5 clones were expressed in
25-ml scale and purified by immobilized metal affinity
chromatography.17
ELISA for binding to LRP1
Human LRP1 (5 nM in 100 ml of TNC buffer) was coated onto
microtiter plates (Corning) overnight at 4 C. Wells were
blocked with 3% bovine serum albumin in TNC (1 h; 37C) and
washed in TNC containing 0.05% Brij-35 after this and each
subsequent step. Wells were then incubated with various concen-
trations of ADAMTS-4 lacking C-terminus spacer domain,
ADAMTS-5–2 or TIMP-3 in blocking solution for 2 h at room
temperature. To compare the levels of bound proteins, the bound
proteins were detected with anti-FLAG M2 antibody (F1804,
Sigma-Aldrich) followed by anti-mouse antibody coupled to
horseradish peroxidase. For screening purposes, biotinylated
ADAMTS-5–2 was used and its binding to LRP1 was detected
by AP-conjugated streptavidin. Hydrolysis of tetramethylbenzi-
dine substrate (KPL) measured at 450 nm using a BioTek EL-
808 absorbance microplate reader (BioTek). Data were fitted to
the One-Site association equation on software package GraphPad
Prism. Each value was normalized by subtracting the amount of
enzyme bound to control wells that were not coated with LRP1.
Biolayer interferometry
1B7 was biotinylated by incubation with a 20-fold excess of EZ-
link succinimidyl 6-(biotinamido) hexanoate (30 min, 25C,
Thermo Fisher Scientific) and biotin excess was removed using
a PD-10 desalting column (GE Healthcare). Biotinylated 1B7
(1 mM) was immobilized on streptavidin-coated biosensors
(5 min, 25C) using an Octet RED384 biolayer interferometer
(Pall ForteBio). To determine the affinity between 1B7 and
ADAMTS-5, antibody-coated biosensors were incubated with
ADAMTS-5–2 (50–500 nM in TNC buffer) or ADAMTS-5–5
(50–1600 nM), and association was observed for 5 min at 25C.
Tips were then incubated in TNC buffer for a further 10 min at
25C to observe dissociation of the complex. No binding of
ADAMTS-5 to uncoated biosensors was observed. Kinetic con-
stants were calculated using a 1:1 binding model in ForteBio
OctetRED evaluation data analysis software as described
previously.37 KD was calculated from equilibrium responses,
and koff was calculated by determining the first-order rate
constant. Observed association rate constant (kobs) values were
calculated by determining the second-order rate constant, and
kon was calculated from linear regression of kobs on ADAMTS-5
concentration.
Human cartilage tissue preparation and isolation of
chondrocytes
Normal human articular cartilage tissues were obtained from
the Stanmore BioBank, Institute of Orthopaedics, Royal
National orthopedic Hospital, Stanmore from patients follow-
ing informed consent and approval by the Royal Veterinary
College Ethics and Welfare Committee (Institutional approval
URN 2012 0048H). Cartilage from human femoral condyles of
the knee joints was used. Normal articular cartilage was
obtained from patients following knee amputation due to soft
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tissue sarcoma and osteosarcoma with no involvement of the
cartilage. Tissues were obtained from 5 patients (3 males aged
18, 23 and 57 yrs; 2 females aged 19 and 68 yrs). Chondrocytes
were isolated as described previously.16 Both primary and pas-
saged human cells were used in the experiments.
Analysis of ADAMTS-5 endocytosis
Cells (5 £ 104) cultured in 24-well plates were rested in 500 ml
of Dulbecco’s Modified Eagle Medium (DMEM) for 1 day. The
medium was replaced with 500 ml of fresh DMEM with 10 nM
of purified human ADAMTS-5–2 in the absence or presence of
the antibodies (each 100 nM) or 500 nM RAP at 37C. After
incubation for 0–4 h, media were collected and the protein was
precipitated with 5% trichloroacetic acid and dissolved in 50 ml
of 1x SDS-sample buffer containing 5% 2-mercaptoethanol. All
samples were analyzed by SDS-PAGE under reducing condi-
tions and Western blotting using anti-FLAG M2 mouse mono-
clonal antibody. Immune signals for exogenously added
ADAMTS-5–2 detected in the medium were acquired using
ImageScannerIII (GE Healthcare) and quantified with ImageJ
quantification software. The amount of ADAMTS-5–2 remain-
ing in the medium at each time point was calculated as a per-
centage of the amount of the enzyme at 0 h.
Detection of aggrecanolytic activity in cultured human
chondrocytes
The aggrecanase activity in culture medium of human chon-
drocytes was detected as described previously.38 Briefly, cells
were plated at a density of 5£104 cells/well (24-well plate) in
DMEM with 10% fetal bovine serum. Cells were rested for 24 h
in DMEM and then overlaid with sterile filtered bovine aggre-
can (100 mg/ml) in DMEM containing 50 mg/ml of polymyx-
inB in the absence or presence of the antibodies or N-TIMP-3
(each 100 nM) for 0–72 h. To evaluate aggrecan degradation
products in chondrocytes cultures, 200 ml of conditioned
medium were collected and aggrecanase-generated fragments
were detected by Western blot analysis as described above. All
data were analyzed by unpaired one-tail t tests with Welch’s
correction using the software package GraphPad Prism.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
Fundings
The work was supported by Arthritis Research UK (20563), Arthritis
Research UK Center for Osteoarthritis Pathogenesis (20205), Cancer
Research UK (C100/A8243), the Kennedy Trust for Rheumatology
Research, orthopedic Research UK (483) and the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (AR40994).
References
1. Fushimi K, Troeberg L, Nakamura H, Lim NH, Nagase H. Functional
Differences of the Catalytic and Non-catalytic Domains in Human
ADAMTS-4 and ADAMTS-5 in Aggrecanolytic Activity. J Biol Chem
2008; 283:6706-16; PMID:18156631; http://dx.doi.org/10.1074/jbc.
M708647200
2. DurigovaM, Nagase H,Mort JS, Roughley PJ. MMPs are less efficient than
ADAMTS5 in cleaving aggrecan core protein.Matrix Biol 2011; 30:145-53;
PMID:21055468; http://dx.doi.org/10.1016/j.matbio.2010.10.007
3. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL,
Flannery CR, Peluso D, Kanki K, Yang Z, et al. Deletion of active
ADAMTS5 prevents cartilage degradation in a murine model of oste-
oarthritis. Nature 2005; 434:644-8; PMID:15800624; http://dx.doi.org/
10.1038/nature03369
4. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT,
Little CB, Last K, Farmer PJ, Campbell IK, et al. ADAMTS5 is the major
aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005;
434:648-52; PMID:15800625; http://dx.doi.org/10.1038/nature03417
5. Larkin J, Lohr TA, Elefante L, Shearin J, Matico R, Su JL, Xue Y, Liu F,
Genell C, Miller RE, et al. Translational development of an
ADAMTS-5 antibody for osteoarthritis disease modification. Osteoar-
thritis Cartilage 2015; 23:1254-66; PMID:25800415; http://dx.doi.org/
10.1016/j.joca.2015.02.778
6. McCulloch DR, Le Goff C, Bhatt S, Dixon LJ, Sandy JD, Apte SS.
Adamts5, the gene encoding a proteoglycan-degrading metallopro-
tease, is expressed by specific cell lineages during mouse embryonic
development and in adult tissues. Gene Expr Patterns 2009; 9:314-23;
PMID:19250981; http://dx.doi.org/10.1016/j.gep.2009.02.006
7. Stupka N, Kintakas C, White JD, Fraser FW, Hanciu M, Aramaki-
Hattori N, Martin S, Coles C, Collier F, Ward AC, et al. Versican
Processing by a Disintegrin-like and Metalloproteinase Domain with
Thrombospondin-1 Repeats Proteinases-5 and -15 Facilitates Myo-
blast Fusion. J Biol Chem 2013; 288:1907-17; PMID:23233679; http://
dx.doi.org/10.1074/jbc.M112.429647
8. Gendron C, Kashiwagi M, Lim NH, Enghild JJ, Thogersen IB, Hughes
C, Caterson B, Nagase H. Proteolytic Activities of Human ADAMTS-
5: COMPARATIVE STUDIES WITH ADAMTS-4. J Biol Chem 2007;
282:18294-306; PMID:17430884; http://dx.doi.org/10.1074/jbc.
M701523200
9. Dupuis LE, McCulloch DR, McGarity JD, Bahan A, Wessels A, Weber
D, Diminich AM, Nelson CM, Apte SS, Kern CB. Altered versican
cleavage in ADAMTS5 deficient mice; a novel etiology of myxomatous
valve disease. Dev Biol 2011; 357:152-64; PMID:21749862; http://dx.
doi.org/10.1016/j.ydbio.2011.06.041
10. Longpre JM, McCulloch DR, Koo BH, Alexander JP, Apte SS, Leduc
R. Characterization of proADAMTS5 processing by proprotein con-
vertases. Int J Biochem Cell Biol 2009; 41:1116-26; PMID:18992360;
http://dx.doi.org/10.1016/j.biocel.2008.10.008
11. McCulloch DR, Nelson CM, Dixon LJ, Silver DL, Wylie JD, Lindner
V, Sasaki T, Cooley MA, Argraves WS, Apte SS. ADAMTS metallo-
proteases generate active versican fragments that regulate interdigital
web regression. Dev Cell 2009; 17:687-98; PMID:19922873; http://dx.
doi.org/10.1016/j.devcel.2009.09.008
12. Hattori N, Carrino DA, Lauer ME, Vasanji A, Wylie JD, Nelson CM,
Apte SS. ericellular versican regulates the fibroblast-myofibroblast
transition: a role for ADAMTS5 protease-mediated proteolysis. J Biol
Chem 2011; 286:34298-310; PMID:21828051; http://dx.doi.org/
10.1074/jbc.M111.254938
13. McMahon M, Ye S, Izzard L, Dlugolenski D, Tripp RA, Bean AG,
McCulloch DR, Stambas J. ADAMTS5 Is a Critical Regulator of
Virus-Specific T Cell Immunity. PLoS Biol 2016; 14:e1002580;
PMID:27855162; http://dx.doi.org/10.1371/journal.pbio.1002580
14. Troeberg L, Nagase H. Proteases involved in cartilage matrix degrada-
tion in osteoarthritis. Biochim Biophys Acta 2012; 1824:133-145;
PMID:21777704; http://dx.doi.org/10.1016/j.bbapap.2011.06.020
15. Yamamoto K, Murphy G, Troeberg L. Extracellular regulation of met-
alloproteinases. Matrix Biol 2015; 44-46:255-63; PMID:25701651;
http://dx.doi.org/10.1016/j.matbio.2015.02.007
16. Yamamoto K, Troeberg L, Scilabra SD, Pelosi M, Murphy CL,
Strickland DK, Nagase H. LRP-1-mediated endocytosis regulates extra-
cellular activity of ADAMTS-5 in articular cartilage. FASEB J 2013;
27:511-21; PMID:23064555; http://dx.doi.org/10.1096/fj.12-216671
17. Santamaria S, Yamamoto K, Botkjaer K, Tape C, Dyson MR,
McCafferty J, Murphy G, Nagase H. Antibody-based exosite inhibitors
MABS 601
D
ow
nl
oa
de
d 
by
 [R
oy
al 
Ve
ter
ina
ry
 C
oll
eg
e] 
at 
03
:07
 09
 A
ug
us
t 2
01
7 
of ADAMTS-5 (aggrecanase-2). Biochem J 2015; 471:391-401;
PMID:26303525; http://dx.doi.org/10.1042/BJ20150758
18. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL
receptor-related protein 1: unique tissue-specific functions revealed by
selective gene knockout studies. Physiol Rev 2008; 88:887-918;
PMID:18626063; http://dx.doi.org/10.1152/physrev.00033.2007
19. Koza RA, Nikonova L, Hogan J, Rim JS, Mendoza T, Faulk C, Skaf J,
Kozak LP. Changes in gene expression foreshadow diet-induced obe-
sity in genetically identical mice. PLoS Genet 2006; 2:e81;
PMID:16733553; http://dx.doi.org/10.1371/journal.pgen.0020081
20. Yamamoto K, Owen K, Parker AE, Scilabra SD, Dudhia J, Strickland
DK, Troeberg L, Nagase H. Low density lipoprotein receptor-related
protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and
metalloproteinase with thrombospondin motifs-4 (ADAMTS-4):
functional differences of non-catalytic domains of ADAMTS-4 and
ADAMTS-5 in LRP1 binding. J Biol Chem 2014; 289:6462-74;
PMID:24474687; http://dx.doi.org/10.1074/jbc.M113.545376
21. Lenting PJ, Neels JG, van den Berg BM, Clijsters PP, Meijerman
DW, Pannekoek H, van Mourik JA, Mertens K, van Zonneveld
AJ. The light chain of factor VIII comprises a binding site for low
density lipoprotein receptor-related protein. J Biol Chem 1999;
274:23734-9; PMID:10446132; http://dx.doi.org/10.1074/
jbc.274.34.23734
22. Dupont DM, Thuesen CK, Botkjaer KA, Behrens MA, Dam K,
Sorensen HP, Pedersen JS, Ploug M, Jensen JK, Andreasen PA. Pro-
tein-binding RNA aptamers affect molecular interactions distantly
from their binding sites. PLoS ONE 2015; 10:e0119207;
PMID:25793507; http://dx.doi.org/10.1371/journal.pone.0119207
23. Bjerregaard N, Botkjaer KA, Helsen N, Andreasen PA, Dupont DM.
Tissue-type plasminogen activator-binding RNA aptamers inhibiting
low-density lipoprotein receptor family-mediated internalisation.
Thromb Haemost 2015; 114:139-49; PMID:25855589; http://dx.doi.
org/10.1160/TH14-08-0686
24. Chen S, Bu G, Takei Y, Sakamoto K, Ikematsu S, Muramatsu T, Kado-
matsu K. Midkine and LDL-receptor-related protein 1 contribute to the
anchorage-independent cell growth of cancer cells. J Cell Sci 2007;
120:4009-015; PMID:17971413; http://dx.doi.org/10.1242/jcs.013946
25. Scilabra SD, Yamamoto K, Pigoni M, Sakamoto K, Muller SA, Papa-
dopoulou A, Lichtenthaler SF, Troeberg L, Nagase H, Kadomatsu K.
Dissecting the interaction between tissue inhibitor of metalloprotei-
nases-3 (TIMP-3) and low density lipoprotein receptor-related pro-
tein-1 (LRP-1): Development of a “TRAP” to increase levels of TIMP-
3 in the tissue. Matrix Biol 2016; 59:69-79; PMID:27476612; http://dx.
doi.org/10.1016/j.matbio.2016.07.004
26. Scilabra SD, Troeberg L, Yamamoto K, Emonard H, Thogersen I,
Enghild JJ, Strickland DK, Nagase H. Differential regulation of extra-
cellular tissue inhibitor of metalloproteinases-3 levels by cell mem-
brane-bound and shed low density lipoprotein receptor-related
protein 1. J Biol Chem 2013; 288:332-342; PMID:23166318; http://dx.
doi.org/10.1074/jbc.M112.393322
27. Yamamoto K, Okano H, Miyagawa W, Visse R, Shitomi Y, Santamaria
S, Dudhia J, Troeberg L, Strickland DK, Hirohata S, et al. MMP-13 is
constitutively produced in human chondrocytes and co-endocytosed
with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1. Matrix
Biol 2016; 56:57-73; PMID:27084377; http://dx.doi.org/10.1016/j.
matbio.2016.03.007
28. Kawata K, Kubota S, Eguchi T, Aoyama E, Moritani NH, Kondo S,
Nishida T, Takigawa M. Role of LRP1 in transport of CCN2 protein
in chondrocytes. J Cell Sci 2012; 125:2965-72; PMID:22454511; http://
dx.doi.org/10.1242/jcs.101956
29. Llorente-Cortes V, Badimon L. LDL receptor-related protein and the
vascular wall: implications for atherothrombosis. Arterioscler Thromb
Vasc Biol 2005; 25:497-04; PMID:15705932; http://dx.doi.org/
10.1161/01.ATV.0000154280.62072.fd
30. Didangelos A, Mayr U, Monaco C, Mayr M. Novel role of ADAMTS-
5 protein in proteoglycan turnover and lipoprotein retention in ath-
erosclerosis. J Biol Chem 2012; 287:19341-45; PMID:22493487; http://
dx.doi.org/10.1074/jbc.C112.350785
31. Kashiwagi M, Enghild JJ, Gendron C, Hughes C, Caterson B, Itoh Y,
Nagase H. Altered Proteolytic Activities of ADAMTS-4 Expressed by
C-terminal Processing. J Biol Chem 2004; 279:10109-19;
PMID:14662755; http://dx.doi.org/10.1074/jbc.M312123200
32. Troeberg L, Fushimi K, Scilabra SD, Nakamura H, Dive V, Thogersen
IB, Enghild JJ, Nagase H. The C-terminal domains of ADAMTS-4 and
ADAMTS-5 promote association with N-TIMP-3. Matrix Biol 2009;
28:463-69; PMID:19643179; http://dx.doi.org/10.1016/j.matbio.2009.
07.005
33. Troeberg L, Fushimi K, Khokha R, Emonard H, Ghosh P, Nagase H.
Calcium pentosan polysulfate is a multifaceted exosite inhibitor of
aggrecanases. FASEB J 2008; 22:3515-24; PMID:18632849; http://dx.
doi.org/10.1096/fj.08-112680
34. Hascall VC, Sajdera SW. Proteinpolysaccharide complex from bovine
nasal cartilage. The function of glycoprotein in the formation of aggre-
gates. J Biol Chem 1969; 244:2384-96; PMID:5783840
35. Falk R, Falk A, Dyson MR, Melidoni AN, Parthiban K, Young JL,
Roake W, McCafferty J. Generation of anti-Notch antibodies and their
application in blocking Notch signalling in neural stem cells. Methods
2012; 58:69-78; PMID:22842086; http://dx.doi.org/10.1016/j.
ymeth.2012.07.008
36. Schofield DJ, Pope AR, Clementel V, Buckell J, Chapple S, Clarke KF,
Conquer JS, Crofts AM, Crowther SR, Dyson MR, et al. Application
of phage display to high throughput antibody generation and charac-
terization. Genome Biol 2007; 8:R254; PMID:18047641; http://dx.doi.
org/10.1186/gb.2007.8.11.r254
37. Troeberg L, Lazenbatt C, Anower-E-Khuda MF, Freeman C, Federov
O, Habuchi H, Habuchi O, Kimata K, Nagase H. Sulfated glycosami-
noglycans control the extracellular trafficking and the activity of the
metalloprotease inhibitor TIMP-3. Chem Biol 2014; 21(10): 1300-09;
PMID:25176127; http://dx.doi.org/10.1016/j.chembiol.2014.07.014
38. Ismail HM, Yamamoto K, Vincent TL, Nagase H, Troeberg L, Saklat-
vala J. Interleukin 1 acts via c-jun N-terminal kinase-2 signalling path-
way to induce aggrecan degradation by human chondrocytes. Arthritis
Rheumatol 2015; 67(7): 1826-36; PMID:25776267; http://dx.doi.org/
10.1002/art.39099
602 S. SANTAMARIA ET AL.
D
ow
nl
oa
de
d 
by
 [R
oy
al 
Ve
ter
ina
ry
 C
oll
eg
e] 
at 
03
:07
 09
 A
ug
us
t 2
01
7 
